Finder makes money from featured partners, but editorial opinions are our own.

Why is the CSL share price edging higher?


Shares in biotech giant CSL are up 7% in the past month alone.

Shares in CSL (ASX: CSL) are among the list of most traded stocks on the ASX on Wednesday, building on the recent momentum that has seen the already expensive stock gain over 7% in the past month. The stock was up more than 1% to $319.78 in early trading.

What is bolstering the CSL stock price?

The biotech giant’s shares have likely lifted on Wednesday after its influenza vaccine business, Seqirus, overnight announced it had received approval from the the US Food and Drug Administration (FDA) for the Audenz vaccine.

Audenz is the first-ever adjuvanted, cell-based influenza vaccine to help protect individuals 6 months and older against influenza A(H5N1) in the event of a pandemic and is available in multi-dose vial (MDV) form.

It was originally approved by the FDA in 2020 in a single dose, pre-filled syringe (PFS) presentation.

Airborne respiratory diseases such as influenza have been a focus of public health systems worldwide since the COVID-19 pandemic spread in March 2020 and the fresh approval is expected to bolster Seqirus’ product line.

Under the terms of its public-private partnership with the US Department of Health and Human Services (HHS), Seqirus can deliver 150 million influenza vaccine doses to the US government to support an influenza pandemic response within 6 months.

Improving outlook

Meanwhile, CSL is also stepping up its investment in research and development, after launching an incubator program at its new Melbourne headquarters that is designed to commercialise Australian ideas and keep research onshore.

The vaccine maker has inked a deal with the University of Melbourne and the Walter and Eliza Hall Institute to launch the $95 million incubator project, with support from the Victorian government’s Breakthrough Victoria Fund. It will have space for 40 Australian companies looking to move early stage research towards commercialisation.

Analysts also expect a revival for CSL’s major blood products business as centres reopen following the vaccine rollout advancing across the world. Plasma products are the key revenue driver for CSL, with the Behring business generating over US$8 billion in revenue.

Brokers at Macquarie Group last week upgraded CSL shares to "outperform" from "neutral", lifting their price target to $338 a share after noting that easing disruptions in the key US plasma collection market would help CSL.

Considering buying CSL shares?

If you are keen to buy shares in CSL, you can invest through an online share trading platform.

Keep in mind that not all platforms offer the same list of stocks. Some offer US stocks only, so make sure to select a platform that offers ASX-listed stocks.

Choose from the dozens available for Australian investors. Compare the features and fees from the plethora of trading platforms available.

Looking for a low-cost online broker to invest in the stock market? Compare share trading platforms to start investing in stocks and ETFs.

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades. Read the Product Disclosure Statement (PDS) and Target Market Determination (TMD) for the product on the provider's website.

Get more from Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site